Forte Biosciences (FBRX) investor relations material

Executive summary

• FB102, an anti-CD122 monoclonal antibody, is in Phase 2 trials for celiac disease and Phase 1b trials for vitiligo and alopecia areata, with FDA Fast Track Designation for celiac disease.

• Positive Phase 1b celiac disease data announced in June 2025; Phase 2 topline results expected in 2026, with additional readouts for other indications anticipated.

• FB102 targets multi-billion-dollar market opportunities across several autoimmune indications.

• Closed a $172.5M public offering in April 2026, with net proceeds of $162.1M, strengthening liquidity.

• No commercial products or revenue; expects continued operating losses as development progresses.

Financial highlights

• Net loss of $22.1M for Q1 2026, compared to $15.7M in Q1 2025, driven by increased R&D expenses.

• Research and development expenses rose to $20.5M in Q1 2026 from $12.7M in Q1 2025, mainly due to clinical and preclinical activity for FB102.

• General and administrative expenses decreased to $2.0M, aided by a $2.3M interim legal settlement, despite higher stock-based compensation.

• Cash and cash equivalents of $58.2M as of March 31, 2026.

• Accumulated deficit reached $245.5M as of March 31, 2026.

Outlook and guidance

• Existing cash and recent offering proceeds expected to fund operations for at least 12 months from filing.

• Anticipates continued increases in R&D expenses as FB102 advances through clinical trials and expands into additional indications.

• Expects fluctuations in G&A expenses as infrastructure grows to support clinical development.

• Future capital needs remain significant; additional funding will be required for full development and commercialization.